Back to VRTX Stock Lookup

Vertex Pharma (VRTX) – Company Press Releases

Jan 28, 2015 04:01 PM Vertex Reports Full-Year and Fourth Quarter 2014 Financial Results and Provides Guidance for 2015
Jan 11, 2015 08:49 PM Vertex Outlines 2015 Business Priorities to Support the Development, Approval and Launch of New Medicines for the Treatment of People with Cystic Fibrosis
Jan 6, 2015 04:01 PM Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2014 Financial Results
Dec 29, 2014 03:11 PM U.S. Food and Drug Administration Approves KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation
Dec 15, 2014 09:00 AM David Altshuler, M.D., Ph.D., Joins Vertex as Executive Vice President of Global Research and Chief Scientific Officer
Nov 20, 2014 04:01 PM Vertex to Present at Deutsche Bank BioFEST on December 2
Nov 5, 2014 07:00 AM Vertex Submits Applications in the U.S. and Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation

Back to VRTX Stock Lookup